superRCA® Oncology Assays
Cancer mutation detection (e.g., MRD, therapy monitoring)
Key Facts
About Rarity Bioscience
Rarity Bioscience is a Stockholm-based diagnostics company commercializing its proprietary superRCA® technology, an ultrasensitive, multiplex molecular amplification platform. The technology detects mutations at a sensitivity of 1 in 100,000, significantly outperforming standard methods, and utilizes flow cytometry for a fast, cost-efficient readout. Founded in 2021, the company has established a U.S. subsidiary and secured a key validation partnership with ARUP Laboratories, positioning it to capture market share in the growing liquid biopsy space. Its focus is on providing research assays, service testing, and custom kits to enable more accessible and sensitive cancer mutation detection.
View full company profile